Prosecution Insights
Last updated: November 04, 2026
Application No. 17/912,418

SYNTHESIS OF 3'N NUCLEOSIDES THROUGH OXIME INTERMEDIATES AND RELATED COMPOUNDS

Non-Final OA §102
Filed
Sep 16, 2022
Priority
Mar 16, 2020 — provisional 62/990,361 +1 more
Examiner
LEWIS, PATRICK T
Art Unit
1691
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Janssen Biopharma Inc.
OA Round
3 (Non-Final)
74%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
88%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allowance Rate
866 granted / 1171 resolved
+14.0% vs TC avg
Moderate +14% lift
Without
With
+14.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
28 currently pending
Career history
1201
Total Applications
across all art units

Statute-Specific Performance

§101
6.2%
-33.8% vs TC avg
§103
31.5%
-8.5% vs TC avg
§102
19.7%
-20.3% vs TC avg
§112
22.6%
-17.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1171 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under Ex Parte Quayle, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on July 22, 2026, has been entered. Allowable Subject Matter Prosecution on the merits of this application is reopened on claims 23-24 and 26 considered unpatentable for the reasons indicated below: Claim 23 is anticipated by Wang et al. Helvetica Chimica Acta (2004), Vol. 87, pages 327-339 (Wang); claims 24 and 26 are objected to for being dependent upon a rejected base claim. The indicated allowability of claim23-24 and 26 is withdrawn in view of the newly discovered reference(s) to Wang et al. Helvetica Chimica Acta (2004), Vol. 87, pages 327-339 (Wang). Rejections based on the newly cited reference(s) follow. Applicant is advised that the Notice of Allowance mailed April 20, 2026, is vacated. If the issue fee has already been paid, applicant may request a refund or request that the fee be credited to a deposit account. However, applicant may wait until the application is either found allowable or held abandoned. If allowed, upon receipt of a new Notice of Allowance, applicant may request that the previously submitted issue fee be applied. If abandoned, applicant may request refund or credit to a specified Deposit Account. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 23 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Wang et al. Helvetica Chimica Acta (2004), Vol. 87, pages 327-339 (Wang). Wang discloses compound b-26 which is embraced by instant formula (II’), wherein B = thymine; R = PG (e.g., tert-butyldiphenylsilyl); and R2 = F. See Scheme 3. PNG media_image1.png 240 328 media_image1.png Greyscale Wang teaches all of the instantly claimed elements. Thus, claim 23 is anticipated. Conclusion Claims 1-2, 4, 6-8, 10-13, 17-19, 22-24, 26, and 29-30 are pending. Claim 23 is rejected. Claims 24 and 26 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Claims 1-2, 4, 6-8, 10-13, 17-19, 22, and 29-30 are allowed. Contacts Any inquiry concerning this communication or earlier communications from the examiner should be directed to PATRICK T LEWIS whose telephone number is (571)272-0655. The examiner can normally be reached Monday to Friday, 10 AM to 4 PM EST (Maxi Flex). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor can be reached at (571) 272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PATRICK T LEWIS/Primary Examiner, Art Unit 1691 /PL/
Read full office action

Prosecution Timeline

Show 1 earlier event
May 23, 2025
Non-Final Rejection mailed — §102
Sep 17, 2025
Response Filed
Jan 09, 2026
Final Rejection mailed — §102
Apr 06, 2026
Request for Continued Examination
Apr 07, 2026
Response after Non-Final Action
Jul 22, 2026
Request for Continued Examination
Jul 23, 2026
Response after Non-Final Action
Oct 28, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780828
METHODS AND MODIFIED NUCLEOSIDES FOR TREATING CORONAVIRUS INFECTIONS
3y 4m to grant Granted Nov 03, 2026
Patent 12780866
SYNTHESIS OF TRINUCLEOTIDE AND TETRANUCLEOTIDE CAPS FOR MRNA PRODUCTION
3y 1m to grant Granted Nov 03, 2026
Patent 12781220
CHEMICALLY REVERSIBLE 2`-OH ACYLATION PROTECTS RNA FROM HYDROLYTIC AND ENZYMATIC DEGRADATION
3y 1m to grant Granted Nov 03, 2026
Patent 12766138
METHODS AND COMPOSITIONS FOR TREATING VIRAL INFECTIONS WITH DOUBLE AND TRIPLE COMBINATIONS OF ANTIVIRAL AND IMMUNE MODULATING COMPOUNDS
3y 7m to grant Granted Oct 20, 2026
Patent 12760056
METHOD FOR PRODUCING BICYCLIC PHOSPHORAMIDITE
4y 6m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
74%
Grant Probability
88%
With Interview (+14.0%)
2y 3m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1171 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month